Andrews David M, Jones Paul S, Mills Gail, Hind S Lucy, Slater Martin J, Trivedi Naimisha, Wareing Katrina J
GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK.
Bioorg Med Chem Lett. 2003 May 19;13(10):1657-60. doi: 10.1016/s0960-894x(03)00274-9.
Using the pyrrolidine-5,5-trans-lactam template, we have designed small, neutral, mechanism-based inhibitors of hepatitis C NS3/4A protease. Compound 2b, with a spiro-cyclobutyl P1 substituent and an isopropyl carbonyl substituent at the lactam nitrogen, has an IC(50) value in the replicon cell-based assay of 3 microM.
利用吡咯烷-5,5-反式内酰胺模板,我们设计了基于机制的丙肝NS3/4A蛋白酶的小型中性抑制剂。化合物2b在环丁烷螺环P1位有取代基,内酰胺氮上有异丙基羰基取代基,在基于复制子细胞的试验中IC(50)值为3 microM。